Contract

UKRI-1161 Laser Micro-dissection Inverted Imaging System

  • UK Research & Innovation

F03: Contract award notice

Notice identifier: 2021/S 000-003407

Procurement identifier (OCID): ocds-h6vhtk-0294b7

Published 20 February 2021, 9:32am



Section one: Contracting authority

one.1) Name and addresses

UK Research & Innovation

Polaris House, North Star Avenue

Swindon

SN2 1FL

Email

MRCprocurement@ukri.org

Telephone

+44 1793867000

Country

United Kingdom

NUTS code

UK - UNITED KINGDOM

Internet address(es)

Main address

www.ukri.org

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Other activity

Scientific Research


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

UKRI-1161 Laser Micro-dissection Inverted Imaging System

Reference number

UKRI-1161

two.1.2) Main CPV code

  • 38000000 - Laboratory, optical and precision equipments (excl. glasses)
    • LA21 - For laboratory use

two.1.3) Type of contract

Supplies

two.1.4) Short description

Supply of MMI Laser Microdissection Inverted Imaging System with the ability to measure the presence of the oligonucleotide-based drugs (i.e. antisense and siRNA) within the tissue and assess drug action through measurement of changes in the mRNA and protein levels of the drug target. We require a brightfield/fluorescence microscope that can be employed to view, record and quantify tissues stained by H&E, in situ hybrisation (ISH) and immunohistochemistry (IHC). We also require an attached laser that can be employed to provide tissue section down to the single cell level for the analysis of drug, mRNA and protein levels. In addition, we require a system that can be expanded in the future through the addition of a confocal microscope.

two.1.6) Information about lots

This contract is divided into lots: No

two.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £228,115.15

two.2) Description

two.2.3) Place of performance

NUTS codes
  • UK - UNITED KINGDOM
Main site or place of performance

UNITED KINGDOM

two.2.4) Description of the procurement

Supply of MMI Laser Microdissection Inverted Imaging System with the ability to measure the presence of the oligonucleotide-based drugs (i.e. antisense and siRNA) within the tissue and assess drug action through measurement of changes in the mRNA and protein levels of the drug target. We require a brightfield/fluorescence microscope that can be employed to view, record and quantify tissues stained by H&E, in situ hybrisation (ISH) and immunohistochemistry (IHC). We also require an attached laser that can be employed to provide tissue section down to the single cell level for the analysis of drug, mRNA and protein levels. In addition, we require a system that can be expanded in the future through the addition of a confocal microscope.

two.2.5) Award criteria

Price

two.2.11) Information about options

Options: No

two.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

  • The services can be provided only by a particular economic operator for the following reason:
    • absence of competition for technical reasons

Explanation:

This system was chosen as it needed to integrate into current systems and equipment on site and was therefore the only option.

Only the Olympus MMI Laser Microdissection Inverted Imaging System has a modular system which allows the addition, integration and onboarding of these facilities such as confocal microscopy, live cell imaging and high content screening to provide a system that can deliver all of the following functions: live cell imaging, spinning disc confocal and high content screening, whilst retaining the original functionality of the system and without hardware replacement.

Also, we require a laser to micro-dissect single cells and tissue biopsies for quantifiable analysis such as RT-PCR, sequencing and western blotting. The sample capture procedure must be an upward capture system in order to reduce contamination of samples to a minimum. It must be possible to maintain an RNA-ase and DNA-ase free environment.

This is the only equipment able to deliver all the above as an integrated system.

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No


Section five. Award of contract

Contract No

UKRI-1161

A contract/lot is awarded: Yes

five.2) Award of contract

five.2.1) Date of conclusion of the contract

25 January 2021

five.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

five.2.3) Name and address of the contractor

Olympus (Uk) Ltd

KeyMed House, Stock Road, Southend-on-Sea

Essex

SS2 5QH

Email

tom.skelhon@olympus-europa.com

Telephone

+44 1702616333

Country

United Kingdom

NUTS code
  • UK - UNITED KINGDOM
National registration number

N/A

The contractor is an SME

No

five.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £225,905

Total value of the contract/lot: £228,115.15


Section six. Complementary information

six.3) Additional information

To view this notice, please click here:

https://www.delta-esourcing.com/delta/viewNotice.html?noticeId=569061891

GO Reference: GO-2021220-PRO-17818495

six.4) Procedures for review

six.4.1) Review body

UK Research & Innovation

Polaris House, North Star Avenue

Swindon

SN2 1FL

Email

MRCProcurement@ukri.org

Telephone

+44 1793867000

Country

United Kingdom

Internet address

www.ukri.org